Thyroid Eye Disease: Current Perspectives on Multidisciplinary Management

Activity Chair

Terry J. Smith, MD

Frederick G.L. Huetwell Professor

Ophthalmology and Visual Sciences

Professor of Internal Medicine

University of Michigan Medical School

Ann Arbor, MI

Faculty

Giuseppe Barbesino, MD

Assistant Professor of Medicine

Harvard Medical School

Associate Physician

Massachusetts General Hospital

Boston, MA

Christian Nasr, MD, FACE

Chief of Endocrinology

Banner University Medical Group

Clinical Professor

Department of Internal Medicine

Division of Endocrinology

The University of Arizona

College of Medicine – Phoenix

Phoenix, AZ

Prem S. Subramanian, MD, PhD

Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology

Professor of Ophthalmology, Neurology, and Neurosurgery

University of Colorado School of Medicine

Vice Chair for Academic Affairs

Division Head, Neuro-Ophthalmology

University of Colorado Sue Anschutz-Rodgers Eye Center

Aurora, CO

Overview

Thyroid eye disease (TED) is a multifactorial autoimmune disease with widely varied signs and symptoms. It is believed to result from stimulation of several receptors located in the orbital fibroblasts and is usually associated with hyperthyroidism. However, 5% of patients with TED have hypothyroidism, and 5% have no sign of thyroid disease; thus, it is frequently misdiagnosed. Misdiagnosis can place patients at risk for disfigurement and permanent vision loss, because treatment is most effective during the initial active phase of the disease. Multidisciplinary management of the disease is necessary and involves endocrinologists, ophthalmologists, oculoplastic surgeons, as well as other healthcare providers. In this case-based CME activity, an expert panel will help healthcare professionals involved in the management of TED to recognize the pathogenesis of TED and the role of insulin-like growth factor-1 receptor, assess methods to improve differential diagnosis, review the benefits and limitations of available therapies, and implement practices and procedures that improve the multidisciplinary management of patients with this baffling and potentially devastating disease.

Agenda

7:00 PM

Registration and Dinner

7:30 PM

Introduction

Terry J. Smith, MD

7:35 PM

Thyroid Eye Disease: Insulin-like Growth Factor-1 Receptor as a Key Mediator of Disease

Terry J. Smith, MD

7:45 PM

Panel Discussion: Diagnosing a Hidden Disease

Moderated by Christian Nasr, MD

8:00 PM

Case Discussion: Differential Diagnosis

Giuseppe Barbesino, MD

8:05 PM

Thyroid Eye Disease Treatment: What the Endocrinologist Needs to Know

Prem S. Subramanian, MD, PhD

8:25 PM

Case Discussion: Treating Thyroid Eye Disease

Giuseppe Barbesino, MD

8:35 PM

Panel Discussion

Moderated by Terry J. Smith, MD

8:45 PM

Posttest and Question & Answer

9:00 PM

Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Recognize the role of insulin-like growth factor-1 receptor in the pathogenesis of TED.
• Assess modalities that can improve the differential diagnosis of TED.
• Review the benefits and limitations of available therapies used in the treatment of TED.
• Implement practices and procedures that improve the multidisciplinary management of patients with TED.

Target Audience

The intended audience for this activity is endocrinologists and other healthcare professionals involved in the management of patients with TED.